SCHEMBL21472499

SCHEMBL21472499

CCCCNc1c(NCC)c(=O)c1=S

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.36
MAPT P10636 3/20 0.36
TDP1 Q9NUW8 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
KDM4E B2RXH2 4/20 0.36
GAA P10253 3/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
CYP1A2 P05177 1/20 0.33
APAF1 O14727 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
TSHR P16473 1/20 0.32
HTT P42858 2/20 0.32
HCAR3 P49019 1/20 0.31
GPR84 Q9NQS5 1/20 0.30
USP2 O75604 1/20 0.30
LMNA P02545 1/20 0.30
MAPK1 P28482 1/20 0.30
RECQL P46063 1/20 0.30
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21230892 1.00 ALDH1A1 (0.36) ALDH1A1MAPTTDP1L3MBTL1KDM4E
SCHEMBL22645838 0.95 GPR84 (0.36) ALDH1A1MAPTKDM4EGAATSHR
SCHEMBL21473480 0.95 GPR84 (0.36) ALDH1A1MAPTKDM4EGAATSHR
SCHEMBL24806625 0.93 GPR84 (0.37) MAPTSMN1; SMN2HTTGPR84MAPK1
SCHEMBL22645834 0.89 GAA (0.32) KDM4EGAACYP1A2LMNAMAPK1
SCHEMBL21231037 0.89 GAA (0.32) KDM4EGAACYP1A2LMNAMAPK1
SCHEMBL21231244 0.86 ALDH1A1 (0.42) ALDH1A1MAPTTDP1L3MBTL1KDM4E
SCHEMBL21231188 0.86 TSHR (0.39) ALDH1A1MAPTTDP1L3MBTL1KDM4E
SCHEMBL22645842 0.85 ALDH1A1 (0.36) ALDH1A1MAPTTDP1L3MBTL1KDM4E
SCHEMBL22645947 0.85 ALDH1A1 (0.36) ALDH1A1MAPTTDP1L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027864-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS MODERNATX, INC. 2023-01-26 US disclosed
WO-2021022173-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF RNA INTERFERENCE AGENTS TO IMMUNE CELLS MODERNATX, INC. (US) 2021-02-04 WO disclosed
WO-2020227537-A1 DIFFERENTIALLY EXPRESSED IMMUNE CELL MICRORNAS FOR REGULATION OF PROTEIN EXPRESSION Modernatx, Inc (US) 2020-11-12 WO disclosed
WO-2020061367-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX, INC. (US) 2020-03-26 WO disclosed
US-20190314291-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS MODERNATX, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027864-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS LCP2, CD14, MYD88 ALDH1A1 4722/4885MAPT 2204/4885TDP1 2459/4885
US-20190314291-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS LCP2, CD14, MYD88 ALDH1A1 4722/4885MAPT 2204/4885TDP1 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.